Original Article

The antibacterial activity of mineral trioxide aggregate containing calcium fluoride

Miyoung Lim, Seunghoon Yoo*

Department of Conservative Dentistry, Dankook University College of Dentistry Jukjeon Hospital, Yongin, South Korea

Songha Yoo Seunghoon Pediatric Dentistry, Cheonan, South Korea

Received 28 July 2021; Final revision received 1 September 2021
Available online 9 October 2021

KEYWORDS
Antibacterial activity; E. faecalis; Calcium fluoride; MTA; P. endodontalis

Abstract
Background/purpose: Because complete microbial elimination of the infected root canal system is nearly impossible to achieve, the use of root canal fillings with antibacterial effects may help to minimize intracanal infections. Our previous study, MTA modified by CaF₂ addition, improved the biocompatibility and mineralization potential of human dental pulp cells without adverse effect on the physical properties. In this study, the antibacterial effect of MTA after CaF₂ addition was evaluated for use as a root canal sealer. The objective of this study was to evaluate the antibacterial activity of MTA after the addition of CaF₂.

Materials and methods: The antibacterial activities of MTA and MTA—CaF₂ mixture against Enterococcus faecalis (E. faecalis), Porphyromonas endodontalis (P. endodontalis), and Porphyromonas gingivalis (P. gingivalis) were investigated with MTA-CaF₂ powder and eluates. The bacterial growth was measured by optical density using a spectrophotometer and the bacterial colony counting.

Results: MTA inhibited the growth of E. faecalis, P. endodontalis, and P. gingivalis, and the addition of CaF₂ improved this antibacterial effect in a concentration dependent manner (p < 0.05). E. faecalis was more resistant to MTA-CaF₂ than the other groups of bacteria.

Conclusion: The addition of more than 5% CaF₂ to MTA can increase the antibacterial activity.

© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Songha Yoo Seunghoon Pediatric Dentistry, 201, Dujeong-ro 188, Seobuk-gu, Cheonan-si, Chungnam, 31107, South Korea.
E-mail address: yoo.seunghoon@gmail.com (S. Yoo).

https://doi.org/10.1016/j.jds.2021.09.005
1991-7902/© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Considering the indispensable role of microorganisms in the development and progress of pulpal and periapical disease, the eradication of microorganisms from the root canal system and prevention of their invasion is essential for root canal treatment.1–4 However, because complete microbial elimination of the infected root canal system is nearly impossible to achieve, the use of root canal fillings with antibacterial effects may help to minimize intracanal infections. When MTA is used for root canal fillings, to increase its antibacterial effect will be beneficial clinically.5,6

MTA, a calcium silicate-based cement with excellent biological and physical properties,7 was introduced to dentistry in the mid-1990s.8,9 It is able to set and seal even in moist and blood-contaminated environments.10 It is routinely used to induce hard tissue in various procedures, such as root perforation repair, pulp-dentin regeneration, apical barrier formation, pulp capping, pulpotomy, and root-end filling.9,11 With these excellent properties of calcium silicate-based cement, an endodontic sealer based on the calcium silicate has been introduced.12

When calcium silicate based sealer is used for root canal filling, the antibacterial effect will be one of the important properties. Even though there are various calcium silicate-based root canal sealers commercially available on the market, some are still early stages, requiring further laboratory and clinical study, therefore, MTA was used in this study.12 Previous studies have reported conflicting results about the antibacterial activity of MTA.13–15 The antibacterial property of MTA is related to the release of calcium hydroxide and the alkalinizing activity.16

Since the 1940s, fluoride has been reported to affect dental plaque and oral bacteria,17 and it has been used for dental caries prevention. It interferes bacterial metabolism by inhibiting glycolytic enzymes.18,19 CaF2 is one of the widely used fluoride composites, and it has been studied in medical and dental material science for its antibacterial effect.20 Our previous study,23 MTA modified by CaF2 addition, improved the biocompatibility and mineralization potential of human dental pulp cells (HDPCs) without negatively affecting the physical properties. In this study, the antibacterial effect of MTA after CaF2 addition was evaluated for use as a root canal sealer.

The objective of this study was to evaluate the antibacterial activity of MTA after the addition of CaF2.

Materials and methods

The antimicrobial activity of MTA and MTA-CaF2 mixture against Enterococcus faecalis, Porphyromonas endodontalis, and Porphyromonas gingivalis was investigated according to the method of Clinical Laboratory Standard Institute (CLSI). Because the lower solubility of CaF2 could show different result,23 both MTA or MTA-CaF2 powder and eluate were used.

Preparation of MTA samples

ProRoot MTA (Lot number: 212470; Dentsply Sirona, York, PA, USA) and CaF2 powder (Sigma–Aldrich, San Jose, CA, USA) were used in this study. MTA powder was mixed with various concentrations of CaF2 as Table 1.

For the MTA eluate test, the MTA and MTA–CaF2 mixture (2g) was mixed with sterile distilled water (DW; 5 ml) in 15 ml conical tubes (SPL Lifesciences, Pocheon, Korea). The tubes containing MTA and MTA-CaF2 were mixed for 30 s using a vortex mixer (Scientific Industries Inc., Bohemia, NY, USA) and centrifuged at 3000×g for 5 min using the method in the previous study.23 The supernatant was transferred to a new tube for the experiment.

Bacteria culture

E. faecalis ATCC 29212, P. endodontalis ATCC 35406, and P. gingivalis ATCC 33277 were used in this study. E. faecalis was cultivated with brain heart infusion (BHI) (BD Biosciences, Franklin Lakes, NJ, USA) broth. P. endodontalis and P. gingivalis were cultivated in BHI broth supplemented with 0.2 μg/ml of vitamin K (Sigma–Aldrich) and 1 μg/ml of hemin (Sigma–Aldrich). The bacteria were cultured at 37 °C under anaerobic conditions (H2 5%, CO2 10%, and N2 85%).

The cultured bacteria were adjusted to 1.0 × 106 cells/ml for E. faecalis and 1.5 × 106 cells/ml for Porphyromonas spp, respectively, after measuring the bacterial concentration using a bacterial counting chamber (Marienfeld, Lauda-Königshöfen, Germany).

Investigation of antibacterial activity after direct contact with MTA eluate

Suitable media (180 μl) for bacteria were dispensed in each well of a 96-well plate (SPL Lifesciences), and MTA eluate (180 μl) were then added to the wells of the twelfth row. The eluates were two-fold serially diluted using a multi-channel micropipette to the second row.

Then, 20 μl of each bacterial suspension was inoculated into the well containing the prepared broth, and the plate was incubated at 37 °C under anaerobic conditions (5% H2, 10% CO2, and 85% N2) for 36 h to culture E. faecalis and 48 h to culture Porphyromonas spp, respectively. The pure bacterial suspension without MTA eluate was used the control group. Bacterial growth was measured by optical density at 660 nm using a spectrophotometer (Biotek, Winooski, VT, USA).

Investigation of antibacterial activity after direct contact with MTA powder

For investigating the direct antibacterial activity of MTA and MTA-CaF2, the powder (total weight of 1 g) of MTA and

| Table 1 | The compositions of each group. |
|--------|------------------------------|
| Group | MTA | MTA + 1% CaF2 | MTA + 5% CaF2 | MTA + 10% CaF2 |
| MTA   | 1 g | 0.99 g | 0.95 g | 0.9 g |
| CaF2  | 0 g | 0.01 g | 0.05 g | 0.1 g |

MTA; mineral trioxide aggregate, CaF2; calcium fluoride.
MTA-CaF₂ was placed into a 15 ml conical tube. BHI broth (4.5 ml) was added, and the bacterial suspension (500 μl) was inoculated into the prepared tube. Then, the tube was incubated at 37 °C with shaking for 10 min.

A 10-fold serial dilution (from 10 to 10⁶) of the suspension in the incubated tube was performed using BHI broth. Each dilution of E. faecalis was spread on a BHI agar plate. P. endodontalis and P. gingivalis were spread on a blood agar plate containing hemin and vitamin K. The plates were incubated at 37 °C under anaerobic condition (H₂ 5%, CO₂ 10%, and N₂ 85%) for 36 h and 48 h to culture E. faecalis and Porphyromonas spp, respectively. The bacterial colonies were counted, and expressed as colony-forming unit (CFU). CFU was calculated according to the following equation.

\[
\text{CFU/ml} = \frac{\text{No. of bacterial colonies} \times \text{dilution factor}}{\text{volume of culture transferred to plate}}
\]

**Statistical analysis**

SPSS 23.0 (IBM Software, Armonk, NY, USA) was used for statistical analysis. Normality was verified with Shapiro–Wilk tests. A non-parametric Kruskal–Wallis test was carried out and post-hoc analysis was performed with the Mann–Whitney U test. Statistical significance was considered at \( p < 0.05 \). All data from repeated tests are described as median and interquartile range.

**Results**

**Antibacterial activity with MTA eluate**

MTA and MTA–CaF₂ mixture showed inhibitory effects on the growth of all the bacteria. In the E. faecalis test, bacterial growth was inhibited from 50 mg/ml. P. gingivalis and P. endodontalis were inhibited from 1.6 mg/ml.

1) E. faecalis

Bacterial growth inhibition began at 50 mg/ml of the MTA-5% CaF₂ and MTA-10% CaF₂ groups, but pure MTA and MTA-1% CaF₂ groups showed inhibition effects only at 200 mg/ml (\( p < 0.05 \)). There was no difference between the pure MTA and MTA-1% CaF₂ groups. The MTA-1% CaF₂ and the MTA-5% CaF₂ groups showed differences at 100 and 200 mg/ml, with greater differences detected at 100 mg/ml (\( p < 0.05 \)). The MTA-5% CaF₂ and MTA-10% CaF₂ groups showed differences at 50 and 100 mg/ml, with greater differences observed at 100 mg/ml (\( p < 0.05 \)). However, there was no difference between 5% and 10% CaF₂ groups at 200 mg/ml (Fig. 1).

2) P. endodontalis

P. endodontalis growth was inhibited from 1.6 mg/ml of the MTA-10% CaF₂, while pure MTA showed an effect from 25 mg/ml (\( p < 0.05 \)). Pure MTA and MTA-1% CaF₂ showed no difference except at 25 mg/ml. MTA-1% CaF₂ and 5% CaF₂ showed different effects from 3.2 to 25 mg/ml (\( p < 0.05 \)). Differences between MTA-5% CaF₂ and MTA-10% CaF₂ were detected from 1.6 to 6.25 mg/ml (\( p < 0.05 \)). Differences among the CaF₂ addition groups disappeared after 50 mg/ml. Therefore, after 50 mg/ml, all MTA groups had similar effects on P. endodontalis (Fig. 1).

3) P. gingivalis

P. gingivalis growth was inhibited from 1.6 mg/ml of the MTA-10% CaF₂ and pure MTA showed an antibacterial effect from 25 mg/ml (\( p < 0.05 \)). Pure MTA and MTA-1% CaF₂ showed no difference. The MTA-1% CaF₂ and the MTA-5% CaF₂ showed a difference from 3.2 mg/ml to 25 mg/ml (\( p < 0.05 \)). The MTA-5% CaF₂ and the MTA-10% CaF₂ showed a different effect from 1.6 mg/ml to 6.25 mg/ml (\( p < 0.05 \)). From 50 mg/ml, all MTA groups show similar effects on P. gingivalis (Fig. 1).

![Figure 1](image-url)  
**Figure 1** Antibacterial activity of MTA and MTA-CaF₂ eluates. E. faecalis, P. endodontalis and P. gingivalis were cultivated in the presence or absence of the eluate from MTA and MTA-CaF₂ mixture. Growth was measured via a spectrophotometer. The growth inhibition of E. faecalis began at 50 mg/ml of the MTA-5% CaF₂ and MTA-10% CaF₂, but pure MTA and MTA-1% CaF₂ groups showed inhibition effects only at 200 mg/ml (\( p < 0.05 \)). The MTA-1% CaF₂ and the MTA-5% CaF₂ groups showed differences at 100 and 200 mg/ml. The MTA-5% CaF₂ and MTA-10% CaF₂ groups showed differences at 50 and 100 mg/ml. However, there was no difference between 5% and 10% CaF₂ groups at 200 mg/ml. The growth P. endodontalis and P. gingivalis were inhibited from 1.6 mg/ml of the MTA-10% CaF₂, while pure MTA showed an effect from 25 mg/ml (\( p < 0.05 \)). Differences between MTA-5% CaF₂ and MTA-10% CaF₂ were detected from 1.6 to 6.25 mg/ml (\( p < 0.05 \)). Differences among the CaF₂ addition groups disappeared after 50 mg/ml.
Investigations with direct contact with MTA power

Results of each bacterium are described below and shown in Table 2 and Fig. 2.

1) *E. faecalis*

MTA groups showed an antibacterial effect on *E. faecalis* (*p < 0.05*). Pure MTA and MTA-1% CaF$_2$ groups showed similar effects (*p > 0.05*). The addition of 5% and 10% CaF$_2$ significantly reduced the CFU/ml (*p < 0.05*) (Fig. 2).

2) *P. endodontalis*

MTA groups showed an antibacterial effect on *P. endodontalis*. The addition of CaF$_2$ further reduced the CFU/ml (*p < 0.05*) (Fig. 2).

3) *P. gingivalis*

MTA groups showed a significant antibacterial effect on *P. gingivalis*. The antibacterial effects increased with the concentration of CaF$_2$ (*p < 0.05*) (Fig. 2).

Discussion

Antibacterial activity is derived from MTA’s main components, such as tricalcium silicate and dicalcium silicate. These components hydrate to form an alkaline calcium silicate gel when mixed with water. Calcium hydroxide from this calcium silicate matrix releases hydroxyl ions, resulting in high alkalinity, inhibiting microbial growth.$^{24,25}$ MTA was reported to maintain a high pH in the range of 11–12 for 78 days.$^{26}$

For investigating the antibacterial effect of MTA-CaF$_2$ mixtures, three bacteria were used in this study: *P. gingivalis*, *P. endodontalis*, and *E. faecalis*. *P. gingivalis*, a bacterium related to periodontal disease was included because it is also frequently detected in subgingival plaque from endo-perio combined lesions, necrotic pulp,$^{27}$ and odontogenic abscesses in patients not suffering from periodontal disease.$^{28}$ *E. faecalis* is the most frequently isolated bacterium in recalcitrant infections after endodontic treatment.$^{29,30}$

Previous studies have reported conflicting results regarding the antibacterial activity of MTA on *E. faecalis*. MTA was reported to fail to inhibit the growth of *E. faecalis*.$^{14,15}$ However, other studies have reported that MTA has antibacterial effects on *E. faecalis*.$^{31,32}$ *E. faecalis* is retarded at a pH of 10.5–11.0, and the bacteria cannot survive at a pH higher than 11.5.$^{33}$

In this study, MTA and CaF$_2$ showed antibacterial effects on the bacteria tested. As CaF$_2$ is less soluble, there could be a difference between direct contact with MTA-CaF$_2$ powder and its use as an eluate. Therefore, the antibacterial activities of direct contact with MTA-CaF$_2$ powder were also investigated. Contact with powder is related to the direct influence of MTA, and effects are limited to the surface it contacts. The effect of MTA eluate is limited to the soluble fraction and could affect the distant area.

| Groups          | *E. faecalis*   | *P. endodontalis* | *P. gingivalis*   |
|-----------------|-----------------|-------------------|------------------|
| Control         | 957.500 ± 80.00$^a$ | 1200 ± 195.00$^a$  | 1170 ± 150.00$^l$ |
| MTA             | 155.000 ± 34.31$^b$  | 42.000 ± 16.43$^f$  | 40.875 ± 16.75$^s$ |
| MTA + 1% CaF$_2$| 160.250 ± 24.75$^b$  | 24.375 ± 18.25$^g$  | 17.500 ± 7.75$^l$ |
| MTA + 5% CaF$_2$| 9.850 ± 1.356$^c$    | 1.035 ± 20.75$^b$   | 1.240 ± 0.255$^m$ |
| MTA + 10% CaF$_2$| 5.650 ± 1.612$^d$   | 0.431 ± 0.075$^l$   | 0.515 ± 0.173$^n$ |

CFU: colony-forming unit. Different superscripts indicate significantly different antibacterial activity for different bacteria (*p < 0.05*) (median ± interquartile).

![Figure 2](https://example.com/figure2.png)

**Figure 2**  CFU/ml after direct MTA and MTA-CaF$_2$ powder contact. Dilution of *E. faecalis*, *P. endodontalis* and *P. gingivalis* mixed with MTA and MTA-CaF$_2$ powder was spread on a BHI agar plate. After incubation, bacterial colonies were counted. MTA groups reduced CFU/ml, and the antibacterial effects increased with the concentration of CaF$_2$ (*p < 0.05*). In *E. faecalis*, pure MTA and MTA-1% CaF$_2$ showed similar antibacterial effect. Different superscripts indicate different antibacterial activity (*p < 0.05*).
Both MTA as a powder and as an eluate showed antibacterial effects that increased with CaF₂. MTA inhibited the growth of three bacteria. The addition of CaF₂ improved this antibacterial effect. *E. faecalis* was more resistant to MTA powder and eluates than the other bacteria groups.

In eluate test, MTA-10% CaF₂ and MTA-5% CaF₂ inhibited the growth of *E. faecalis* from 50 mg/ml. Pure MTA and MTA-1% CaF₂ showed the antibacterial effect only at 200 mg/ml. In *P. gingivalis* and *P. endodontalis*, MTA-10% CaF₂ MTA inhibited the growth of three bacteria from 1.6 mg/ml and MTA-5% CaF₂ from 3.2 mg/ml. Pure MTA and MTA-1% CaF₂ showed the antibacterial effect from 25 mg/ml. However, from 50 mg/ml MTA-CaF₂, all MTA groups showed similar antibacterial activity. As a result, *E. faecalis* needs more concentrated extracts than the other two bacteria for growth inhibition.

In the powder test, the addition of CaF₂ improved the antibacterial activity of MTA. These antibacterial effects increased with the concentration of CaF₂. In *E. faecalis*, pure MTA and MTA-1% CaF₂ showed a similar antibacterial effect. From these results, in *E. faecalis*, more than 5% CaF₂ addition is recommended.

From the previous study, less soluble CaF₂ decreased calcium silicate cement hydration, resulting in a lower alkalinizing activity, and CaF₂-treated tricalcium silicate showed a lower pH than pure MTA. Therefore, it could be presumed that the antibacterial activities of MTA-CaF₂ are more related to the inhibition of bacterial metabolism by fluoride than by the alkalinizing activity of MTA.

Torabinejad et al. reported that mixing MTA with chlorhexidine improved its antibacterial properties, but adversely affected biocompatibility. However, from our previous study and the current study, CaF₂ addition to MTA improved both antibacterial effect and biocompatibility. It is speculated that the fluoride level within the eluate was not high enough to be toxic to human dental pulp cells because only the soluble fraction of MTA or CaF₂ could affect the cells. The dissolved fluoride from CaF₂ could be the key to the proliferation and osteogenic stimulation of the pulp cells and the antibacterial effects. Importantly, CaF₂ is regarded as a relatively benign fluoride composite due to its low solubility and ionization.

We conclude that the addition of more than 5% CaF₂ shows better antibacterial effects against *E. faecalis*, *P. endodontalis*, and *P. gingivalis* than pure MTA both in its powder form or in its eluate. The addition of CaF₂ can be considered to increase the antibacterial activity of MTA. However, further studies, including long-term evaluations, are necessary for clinical applications.

**Declaration of competing interest**

The authors declare no conflicts of interest.

**Acknowledgements**

The authors would like to thank Sung-Hoon Lee (Department of Microbiology and Immunology, College of Dentistry, Dankook University, Cheonan, Korea) for advice and support.

**References**

1. Kakehashi S, Stanley HR, Fitzgerald RJ. The effects of surgical exposures of dental pulps in germ-free and conventional laboratory rats. Oral Surg Oral Med Oral Pathol 1965;20:340–9.
2. Möller AJ, Fabricius L, Dahlén G, Ohman AE, Heyden G. Influence on periapical tissues of indigenous oral bacteria and necrotic pulp tissue in monkeys. Scand J Dent Res 1981;89:475–84.
3. Siqueira Jr JF, Rôças IN, Souto R, de Uzeda M, Colombo AP. Checkerboard DNA-DNA hybridization analysis of endodontic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:744–8.
4. Sundqvist G. Ecology of the root canal flora. J Endod 1992;18:427–30.
5. Sjögren U, Figdor D, Persson S, Sundqvist G. Influence of infection at the time of root filling on the outcome of endodontic treatment of teeth with apical periodontitis. Int Endod J 1997;30:297–306.
6. Zhang H, Shen Y, Ruse ND, Haapasalo M. Antibacterial activity of endodontic sealers by modified direct contact test against Enterococcus faecalis. J Endod 2009;35:1051–5.
7. Lee SJ, Monsef M, Torabinejad M. Sealing ability of a mineral trioxide aggregate for repair of lateral root perforations. J Endod 1993;19:541–4.
8. Camilleri J, Montesin FE, Brady K, Sweeney R, Curtis RV, Ford TR. The constitution of mineral trioxide aggregate. Dent Mater 2005;21:297–303.
9. Pariroh M, Torabinejad M. Mineral trioxide aggregate: a comprehensive literature review—part I: chemical, physical, and antibacterial properties. J Endod 2010;36:16–27.
10. Prati C, Gandolfi MG. Calcium silicate bioactive cements: biological perspectives and clinical applications. Dent Mater 2015;31:351–70.
11. Darvell BW, Wu RC. MTA®-an hydraulic silicate cement: review update and setting reaction. Dent Mater 2011;27:407–22.
12. Lim M, Jung C, Shin DH, Cho YB, Song M. Calcium silicate-based root canal sealers: a literature review. Restor Dent Endod 2020;45:e35.
13. Estrela C, Bammann LL, Estrela CR, Silva RS, Pécora JD. Antimicrobial and chemical study of MTA, Portland cement, calcium hydroxide paste, Sealapex and Dycal. Mater Mater 2005;21:403–6.
14. Torabinejad M, Hong CU, Pitt Ford TR, Kettering JD. Antibacterial effects of some root end filling materials. J Endod 1995;21:403–6.
15. Torabinejad M, Hong CU, McDonald F, Pitt Ford TR. Physical and chemical properties of a new root-end filling material. J Endod 1995;21:349–53.
16. Hamilton IR. Biochemical effects of fluoride on oral bacteria. Spec No J Dent Res 1990;69:660–7. discussion 82–3.
17. Marquis RE. Antimicrobial actions of fluoride for oral bacteria. Can J Microbiol 1995;41:955–64.
18. Jeong SH, Shin DY, Kang IK, et al. Effective wound healing by antibacterial and bioactive calcium-fluoride-containing
composite hydrogel dressings prepared using in situ precipitation. *ACS Biomater Sci Eng* 2018;4:2380–9.

21. Łukomska-Szymańska M, Zarzycka B, Grzegorczyk J, et al. Antibacterial properties of calcium fluoride-based composite materials: in vitro study. *BioMed Res Int* 2016;2016:1048320.

22. Xu HH, Moreau JL, Sun L, Chow LC. Strength and fluoride release characteristics of a calcium fluoride based dental nanocomposite. *Biomaterials* 2008;29:4261–7.

23. Miyoung L, Minju S, Chan-Ul H, Yong-bum C. The biocompatibility and mineralization potential of mineral trioxide aggregate containing calcium fluoride—An in vitro study. *J Dent Sci* 2021;16:1080–6.

24. Camilleri J, Pitt Ford TR. Mineral trioxide aggregate: a review of the constituents and biological properties of the material. *Int Endod J* 2006;39:747–54.

25. Dammaschke T, Gerth HU, Züchner H, Schäfer E. Chemical and physical surface and bulk material characterization of white ProRoot MTA and two Portland cements. *Dent Mater* 2005;21:731–8.

26. Fridland M, Rosano R. MTA solubility: a long term study. *J Endod* 2005;31:376–9.

27. Gomes BPFA, Pinheiro ET, Gade-Neto CR, et al. Microbiological examination of infected dental root canals. *Oral Microbiol Immunol* 2004;19:71–6.

28. Sundqvist G, Johansson E, Sjögren U. Prevalence of black-pigmented bacteroides species in root canal infections. *J Endod* 1989;15:13–9.

29. Stuart CH, Schwartz SA, Beeson TJ, Owatz CB. *Enterococcus faecalis*: its role in root canal treatment failure and current concepts in retreatment. *J Endod* 2006;32:93–8.

30. Sundqvist G, Figdor D, Persson S, Sjögren U. Microbiologic analysis of teeth with failed endodontic treatment and the outcome of conservative re-treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998;85:86–93.

31. Al-Hezaimi K, Al-Shalan TA, Naghshbandi J, Oglesby S, Simon JH, Rolstei n I. Antibacterial effect of two mineral trioxide aggregate (MTA) preparations against *Enterococcus faecalis* and *Streptococcus sanguis* in vitro. *J Endod* 2006;32:1053–6.

32. Tanomaru-Filho M, Tanomaru JM, Barros DB, Watanabe E, Ito IY. In vitro antimicrobial activity of endodontic sealers, MTA-based cements and Portland cement. *J Oral Sci* 2007;49:41–5.

33. McHugh CP, Zhang P, Michalek S, Eleazer PD. pH required to kill *Enterococcus faecalis* in vitro. *J Endod* 2004;30:218–9.

34. Lin Q, Li Y, Lan X, Lu C, Chen Y, Xu Z. The apatite formation ability of CaF₂ doping tricalcium silicates in simulated body fluid. *Biomed Mater* 2009;4:045005.

35. Torabinejad M, Parirokh M. Mineral trioxide aggregate: a comprehensive literature review—part II: leakage and biocompatibility investigations. *J Endod* 2010;36:190–202.

36. Gosselin RE, Gleason MN, Hodge HC, Smith RP. *Clinical toxicology of commercial products: acute poisoning*. Williams & Wilkins, 1976.